Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

120 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Atezolizumab/bevacizumab or lenvatinib in hepatocellular carcinoma: Multicenter real-world study with focus on bleeding and thromboembolic events.
Ben Khaled N, Möller M, Jochheim LS, Leyh C, Ehmer U, Böttcher K, Pinter M, Balcar L, Scheiner B, Weich A, Leicht HB, Zarka V, Ye L, Schneider J, Piseddu I, Öcal O, Rau M, Sinner F, Venerito M, Gairing SJ, Förster F, Mayerle J, De Toni EN, Geier A, Reiter FP. Ben Khaled N, et al. Among authors: de toni en. JHEP Rep. 2024 Apr 8;6(6):101065. doi: 10.1016/j.jhepr.2024.101065. eCollection 2024 Jun. JHEP Rep. 2024. PMID: 38798717 Free PMC article.
Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior immune checkpoint inhibitor-based combination therapies: a multicenter retrospective study.
Roessler D, Öcal O, Philipp AB, Markwardt D, Munker S, Mayerle J, Jochheim LS, Hammer K, Lange CM, Geier A, Seidensticker M, Reiter FP, De Toni EN, Ben Khaled N. Roessler D, et al. Among authors: de toni en. J Cancer Res Clin Oncol. 2023 Jul;149(7):3065-3073. doi: 10.1007/s00432-022-04206-8. Epub 2022 Jul 21. J Cancer Res Clin Oncol. 2023. PMID: 35864269 Free PMC article.
Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial.
Seidensticker M, Öcal O, Schütte K, Malfertheiner P, Berg T, Loewe C, Klümpen HJ, van Delden O, Ümütlü MR, Ben Khaled N, de Toni EN, Seidensticker R, Aghdassi A, Tran A, Bronowicki JP, Peynircioglu B, Sangro B, Pech M, Ricke J. Seidensticker M, et al. Among authors: de toni en. JHEP Rep. 2023 Feb 15;5(5):100699. doi: 10.1016/j.jhepr.2023.100699. eCollection 2023 May. JHEP Rep. 2023. PMID: 36968218 Free PMC article.
Changing treatment landscape associated with improved survival in advanced hepatocellular carcinoma: a nationwide, population-based study.
Ben Khaled N, Mörtl B, Beier D, Reiter FP, Pawlowska-Phelan D, Teufel A, Rössler D, Schwade DF, Philipp A, Kubisch I, Ehmer U, Geier A, Lange CM, Mayerle J, Berger-Thürmel K, De Toni EN, Munker S. Ben Khaled N, et al. Among authors: de toni en. Eur J Cancer. 2023 Oct;192:113248. doi: 10.1016/j.ejca.2023.113248. Epub 2023 Jul 21. Eur J Cancer. 2023. PMID: 37672814
Response to the letter re: Changing treatment landscape associated with improved survival in advanced hepatocellular carcinoma: A nationwide, population-based study.
Ben Khaled N, Mörtl B, Beier D, Reiter FP, Pawlowska-Phelan D, Teufel A, Rössler D, Schwade DF, Philipp A, Kubisch I, Ehmer U, Geier A, Lange CM, Mayerle J, Berger K, De Toni EN, Munker S. Ben Khaled N, et al. Among authors: de toni en. Eur J Cancer. 2024 Feb;198:113499. doi: 10.1016/j.ejca.2023.113499. Epub 2023 Dec 15. Eur J Cancer. 2024. PMID: 38160177 No abstract available.
Response to Chen et al.
Ye L, Reiter FP, Guba M, De Toni EN. Ye L, et al. Among authors: de toni en. Clin Transl Gastroenterol. 2020 Aug;11(8):e00205. doi: 10.14309/ctg.0000000000000205. Clin Transl Gastroenterol. 2020. PMID: 32955201 Free PMC article. No abstract available.
120 results